> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Eosinophilic Esophagitis Drug Development
- URL: https://www.fdaweb.com/guidance-on-eosinophilic-esophagitis-drug-development/
- Published: 2020-09-16T12:00:00.000Z
- Updated: 2026-09-14T16:28:56.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147663

*Federal Register* notice: FDA has made available a final guidance entitled *Eosinophilic Esophagitis: Developing Drugs for Treatment*. The document addresses the agency’s current thinking about clinical trials and development programs for such drugs, including recommendations for the necessary attributes of patients for enrollment, trial design, efficacy considerations, safety assessments, and pediatric considerations. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-09-16/pdf/2020-20436.pdf?ref=fdaweb.com).